These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31941644)

  • 21. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
    N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
    Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
    Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
    Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
    Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
    Samanta D
    Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol for epilepsy: trying to see through the haze.
    Detyniecki K; Hirsch LJ
    Lancet Neurol; 2016 Mar; 15(3):235-7. PubMed ID: 26776916
    [No Abstract]   [Full Text] [Related]  

  • 29. Cannabinoids in treatment-resistant epilepsy: A review.
    O'Connell BK; Gloss D; Devinsky O
    Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
    García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
    Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabinoid therapy in epilepsy.
    Billakota S; Devinsky O; Marsh E
    Curr Opin Neurol; 2019 Apr; 32(2):220-226. PubMed ID: 30676535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
    Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
    Klein P; Tolbert D; Gidal BE
    Epilepsy Behav; 2019 Oct; 99():106459. PubMed ID: 31519475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial.
    Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O
    Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epilepsy and cannabidiol: a guide to treatment.
    Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
    Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
    Bergmann KR; Broekhuizen K; Groeneveld GJ
    Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabidiol (Epidiolex) for epilepsy.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):182-184. PubMed ID: 30681657
    [No Abstract]   [Full Text] [Related]  

  • 39. Cannabidiol for Epilepsy: New Hope on the Horizon?
    Sanmartin PE; Detyniecki K
    Clin Ther; 2018 Sep; 40(9):1438-1441. PubMed ID: 30150078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
    CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.